Australia markets closed

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.7000-0.0800 (-4.49%)
As of 12:02PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.7800
Open1.7500
Bid1.6700 x 100
Ask1.7200 x 2500
Day's range1.6700 - 1.7600
52-week range0.3450 - 2.1050
Volume4,022,828
Avg. volume7,764,121
Market cap436.053M
Beta (5Y monthly)3.68
PE ratio (TTM)N/A
EPS (TTM)-0.3200
Earnings date28 Mar 2024 - 31 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.33
  • GlobeNewswire

    Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

    MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO). “I’m very pleased to name Dr. Qamar as the CMO at Ocugen,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. “This appointment recognizes her invaluab

  • GlobeNewswire

    Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

    MALVERN, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the first cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age related macular degeneration (dAMD). GA

  • GlobeNewswire

    Ocugen to Present at Investing in Cures Summit

    MALVERN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will be a panelist at the Investing in Cures Summit 2024 from March 8-9, 2024 at the Fairmont Scottsdale Princess Hotel in Scottsdale, AZ. “I look forward to joining my peers in